The effect of explaining biosimilars in different ways on patients' willingness to switch from a biologic drug to a biosimilar

Not Applicable

Completed

• Conditions: Patients with any kind of health condition who take a biologic medication (e.g., Humira, Enbrel, infliximab, rituximab, tocilizum); Rheumatoid arthritis; Dermatological conditions; Inflammatory and Immune System - Rheumatoid arthritis; Skin - Dermatological conditions

• Registration Number: ACTRN12618000009213
• Lead Sponsor: Keith Petrie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-01-10
• Study Completion: 2018-12-31
• Last Update Posted: 3 March 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 96

Inclusion Criteria

Participants will be included in this study if they:
- are patients attending an appointment with their rheumatologist/dermatologist at a clinic across the Auckland District Health Board,
- are 18 years of age or over,
- take a biologic medication (e.g., Humira, Enbrel, infliximab, rituximab, tocilizumab).

Exclusion Criteria

Participants will be excluded from this study if they:
- are unable to fill out the questionnaires,
- cannot understand, read or write English.

Study & Design

• Study Type: Interventional
• Study Design: Not specified